2019
DOI: 10.1016/j.colsurfb.2019.01.027
|View full text |Cite
|
Sign up to set email alerts
|

Erythropoietin-loaded solid lipid nanoparticles: Preparation, optimization, and in vivo evaluation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
12
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 34 publications
(12 citation statements)
references
References 47 publications
0
12
0
Order By: Relevance
“…As said before, decreasing the amount of lipid incorporated into the formulation frequently helps to reduce particle size, but has a negative effect on the entrapment efficiency (Kurakula et al, 2016;Talluri et al, 2017;Ahmad et al, 2019). Simultaneous optimization of both responses as a function of the formulation components and/or process operational variables allows to find the optimum compromise solution as well as other possible approaches, such as increasing the energy (frequency, speed) during the synthesis to decrease the particle size without sacrificing entrapment efficiency (Nooli et al, 2017;Dara et al, 2019;Khatri et al, 2019;Patel et al, 2019a), or decreasing the surfactant/lipid ratio (Bhalekar et al, 2017;Pandya et al, 2018;Ahmad et al, 2019).…”
Section: The Tiny Big Universe Of Lipid Nanoparticlesmentioning
confidence: 97%
“…As said before, decreasing the amount of lipid incorporated into the formulation frequently helps to reduce particle size, but has a negative effect on the entrapment efficiency (Kurakula et al, 2016;Talluri et al, 2017;Ahmad et al, 2019). Simultaneous optimization of both responses as a function of the formulation components and/or process operational variables allows to find the optimum compromise solution as well as other possible approaches, such as increasing the energy (frequency, speed) during the synthesis to decrease the particle size without sacrificing entrapment efficiency (Nooli et al, 2017;Dara et al, 2019;Khatri et al, 2019;Patel et al, 2019a), or decreasing the surfactant/lipid ratio (Bhalekar et al, 2017;Pandya et al, 2018;Ahmad et al, 2019).…”
Section: The Tiny Big Universe Of Lipid Nanoparticlesmentioning
confidence: 97%
“…It is also a top priority to address these problems, and novel methods have been developed to investigate the flavonoids' utility in animal models through involving new methods and through optimizing its biological applications, like hepatoprotective effectiveness, via the development of formulations [8,9]. One exciting strategy for addressing these issues is the development of NPs as regulated drug delivery systems for increasing the oral bioavailability of hydrophobic and lipophilic drugs such as KFP [10,11]. This may be done in many ways such as specialized uptake mechanisms, long-term release, longer half-lives (t 1/2 ), reduced toxicity, and improved NPs' capacity to traverse physiological boundaries inside the body of an animal.…”
Section: Introductionmentioning
confidence: 99%
“…This way, Dara et al created EPO-loaded SLN to alleviate the restrictions mentioned above. 151 In vivo studies showed that EPO-SLN could protect the animals’ brains from damage caused by an intra-hippocampal injection, with spatial recognition memory considerably recovered compared to rats treated with free EPO. Another synthetic drug, nicotinamide, a histone deacetylase blocker demonstrated in preclinical trials to be beneficial in stopping AD, has poor absorption.…”
Section: Nanoformulations In Combating Neurodegeneration: Pre-clinical Evidencementioning
confidence: 99%
“…This hydrophilic medication was encapsulated in SLN, who functionalized the nanocarriers using polysorbate 80, phosphatidylserine, or phosphatidic acid. 151 When compared to traditional oral nicotinamide, the phosphatidylserine-SLN was efficient in conveying and distributing nicotinamide to the brain in a sustained manner, supposed to lead to cognition enhancement, protection of more neuronal cells (higher neuronal counts in hippocampus subregions) and decrease of tau hyperphosphorylation in an AD rat model.…”
Section: Nanoformulations In Combating Neurodegeneration: Pre-clinical Evidencementioning
confidence: 99%